This site is for informational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult your healthcare provider.
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM | MicrobiomeTrials
← Back to trials NCT07150091
Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Nirogacestat, Lenalidomide, and Dexamethasone in Participants With RRMM Recruiting PHASE1, PHASE2 INTERVENTIONAL
Read the full scientific description See full eligibility requirements Trial Details Start: 2022-07-19Est. Completion: 2025-04-17
Enrollment target: 20 participantsLocations GSK Investigational Site, Boston, Massachusetts, United States GSK Investigational Site, Salvador, Estado de Bahia, Brazil GSK Investigational Site, São Paulo, Brazil GSK Investigational Site, Halifax, Nova Scotia, Canada GSK Investigational Site, Villejuif, France GSK Investigational Site, Hamburg, Germany GSK Investigational Site, Athens, Greece GSK Investigational Site, Mexico City, Mexico GSK Investigational Site, Seoul, South Korea GSK Investigational Site, Seoul, South Korea GSK Investigational Site, Seoul, South Korea GSK Investigational Site, Ulsan, South Korea Other microbiome trials you might be interested in Multiple Myeloma
The purpose of this study is to learn about the study medicine called elranatamab.This study aims to compare elranatamab…
Mobile, United States Est. completion Aug 30, 2026
Multiple Myloma Newly Diagnosed Multiple Myeloma (NDMM)
This is a single-arm, dose-escalation exploratory study evaluating the safety and efficacy of RN1201, a BCMA/CD19-target…
Suzhou, China Est. completion Jan 1, 2027